Management of Patients with Metastatic Medullary Thyroid Carcinoma: | oncology.medicinematters.com Skip to main content

Browse specialties

Breast cancer Genitourinary cancers Lung & thoracic cancers

In focus

Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer

Conferences

SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting

About us

Medicine Matters Oncology

EXTENDED SEARCH

Medicine Matters Oncology

JAVASCRIPT NEEDED

Please enable JavaScript on your browser, so that you can use all features of this website.

INTERNET EXPLORER IS NO LONGER SUPPORTED

Your version of Internet Explorer is no longer supported by this system. Please install one of the following browsers: Microsoft Edge, Safari, Chrome or Firefox

Top

21-07-2016 | Endocrine cancers | Book chapter | Article

Management of Patients with Metastatic Medullary Thyroid Carcinoma: The Role for Systemic Therapy

Latest news
Browse specialties
In focus
Conferences
About us

Version: 0.3578.0